Table 2 Breast cancer relative risk by biomarker level, New York Site of BCFR

OR^a (95% CI)

OR^b (95% CI)

1.19 (0.52, 2.70)

0.77 (0.26, 2.31)

 < 93.95 ng/mL

Reference

Reference

 Elevated (≥ 93.95 ng/mL)

1.46 (0.80, 2.71)

1.37 (0.66, 2.85)

OR^a (95% CI)

OR^c (95% CI)

 Low IGF-1 (< 93.95), low BOADICEA risk (< 3.4%) (N = 27)

Reference

Reference

 Elevated IGF-1 (≥ 93.95), low BOADICEA risk (< 3.4%) (N = 48)

2.49 (0.72, 8.63)

2.76 (0.64, 11.9)

 Low IGF-1 (< 93.95), high BOADICEA risk (≥ 3.4%) (N = 81)

3.23 (0.99, 10.59)

3.74 (0.99, 14.2)

 Elevated IGF-1 (≥ 93.95), high BOADICEA risk (≥ 3.4%) (N = 75)

3.82 (1.20, 12.15)*

3.92 (1.07, 14.4)*

 RERI

− 0.90 (− 4.22, 2.41)

− 1.55 (− 5.80, 2.69)

 p value for interaction

0.28

0.21

OR^a (95% CI)

OR^b (95% CI)

2.76 (0.84, 9.07)

4.90 (0.99, 24.1)

 < 2009

Reference

Reference

 Elevated (≥ 2009)

1.41 (0.79, 2.51)

1.62 (0.81, 3.24)

OR^a (95% CI)

OR^c (95% CI)

 Low IGFBP-3 (< 2009), low BOADICEA risk (< 3.4%) (N = 28)

Reference

Reference

 Elevated IGFBP-3 (≥ 2009), low BOADICEA risk (< 3.4%) (N = 47)

1.52 (0.48, 4.83)

2.08 (0.55, 7.92)

 Low IGFBP-3 (< 2009), high BOADICEA risk (≥ 3.4%) (N = 81)

2.09 (0.71, 6.13)

2.26 (0.70, 7.25)

 Elevated IGFBP-3 (≥ 2009), high BOADICEA risk (≥ 3.4%) (N = 75)

3.24 (1.09, 9.63)*

3.47 (1.04, 11.6)*

 RERI

0.63 (− 1.50, 2.77)

0.13 (− 2.60, 2.86)

 p value for interaction

0.97

0.68